Skip to main content
Erschienen in: Inflammation 2/2017

10.12.2016 | ORIGINAL ARTICLE

Phosphoinositide 3-Kinase Is Involved in Mediating the Anti-inflammation Effects of Vasopressin

verfasst von: Woan-Ching Jan, Ming-Chang Kao, Chen-Hsien Yang, Ya-Ying Chang, Chun-Jen Huang

Erschienen in: Inflammation | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Vasopressin possesses potent anti-inflammatory capacity. Phosphoinositide 3-kinase (PI3K) and its downstream activator Akt contribute to endogenous anti-inflammation capacity. We sought to elucidate whether PI3K is involved in mediating the anti-inflammation effects of vasopressin. Macrophages (RAW264.7 cells) were randomized to receive endotoxin, endotoxin plus vasopressin, or endotoxin plus vasopressin plus the nonselective PI3K inhibitor (LY294002) or the selective isoform inhibitor of PI3Kα (PIK-75), PI3Kβ (TGX-221), PI3Kδ (IC-87114), or PI3Kγ (AS-252424). Compared to macrophages treated with endotoxin, the concentrations of cytokines (tumor necrosis factor-α, interleukin-6) and chemokine (macrophage inflammatory protein-2) in macrophages treated with endotoxin plus vasopressin were significantly lower (all P < 0.05). The concentrations of phosphorylated nuclear factor-κB p65 (p-NF-κB p65) in nuclear extracts and phosphorylated inhibitor-κBα (p-I-κBα) in cytosolic extracts as well as NF-κB-DNA binding activity were also lower (all P < 0.05). Of note, except for macrophages treated with endotoxin plus vasopressin plus PIK-75, the concentrations of cytokines, chemokine, p-NF-κB p65, and p-I-κBα as well as NF-κB-DNA binding activity in macrophages treated with endotoxin plus vasopressin plus LY294002, TGX-221, IC-87114, or AS-252424 were significantly higher than those in macrophages treated with endotoxin plus vasopressin (all P < 0.05). In contrast, the phosphorylated Akt concentration in macrophages treated with endotoxin plus vasopressin was significantly higher than that in macrophages treated with endotoxin or in macrophages treated with endotoxin plus vasopressin plus LY294002, TGX-221, IC-87114, or AS-252424, but not PIK-75. These data confirmed that PI3K, especially the isoforms of PI3Kβ, PI3Kδ, and PI3Kγ, is involved in mediating the anti-inflammatory effects of vasopressin.
Literatur
1.
Zurück zum Zitat Riddell, D.C., R. Mallonee, J.A. Phillips, J.S. Parks, L.A. Sexton, and J.L. Hamerton. 1985. Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somatic Cell and Molecular Genetics 11: 189–95.CrossRefPubMed Riddell, D.C., R. Mallonee, J.A. Phillips, J.S. Parks, L.A. Sexton, and J.L. Hamerton. 1985. Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somatic Cell and Molecular Genetics 11: 189–95.CrossRefPubMed
2.
Zurück zum Zitat Sklar, A.H., and R.W. Schrier. 1983. Central nervous system mediators of vasopressin release. Physiological Reviews 63: 1243–80.PubMed Sklar, A.H., and R.W. Schrier. 1983. Central nervous system mediators of vasopressin release. Physiological Reviews 63: 1243–80.PubMed
3.
Zurück zum Zitat Landry, D.W., H.R. Levin, E.M. Gallant, R.C. Ashton Jr., S. Seo, D. D’Alessandro, et al. 1997. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 5: 1122–5.CrossRef Landry, D.W., H.R. Levin, E.M. Gallant, R.C. Ashton Jr., S. Seo, D. D’Alessandro, et al. 1997. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 5: 1122–5.CrossRef
4.
Zurück zum Zitat Sharshar, T., A. Blanchard, M. Paillard, J.C. Raphael, P. Gajdos, and D. Annane. 2003. Circulating vasopressin levels in septic shock. Critical Care Medicine 31: 1752–8.CrossRefPubMed Sharshar, T., A. Blanchard, M. Paillard, J.C. Raphael, P. Gajdos, and D. Annane. 2003. Circulating vasopressin levels in septic shock. Critical Care Medicine 31: 1752–8.CrossRefPubMed
5.
Zurück zum Zitat Lin, I.Y., H.P. Ma, A.C. Lin, C.F. Chong, C.M. Lin, and T.L. Wang. 2005. Low plasma vasopressin/norepinephrine ratio predicts septic shock. American Journal of Emergency Medicine 23: 718–24.CrossRefPubMed Lin, I.Y., H.P. Ma, A.C. Lin, C.F. Chong, C.M. Lin, and T.L. Wang. 2005. Low plasma vasopressin/norepinephrine ratio predicts septic shock. American Journal of Emergency Medicine 23: 718–24.CrossRefPubMed
6.
Zurück zum Zitat Landry, D.W., H.R. Levin, E.M. Gallant, S. Seo, D. D’Alessandro, M.C. Oz, et al. 1997. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Critical Care Medicine 25: 1279–82.CrossRefPubMed Landry, D.W., H.R. Levin, E.M. Gallant, S. Seo, D. D’Alessandro, M.C. Oz, et al. 1997. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Critical Care Medicine 25: 1279–82.CrossRefPubMed
7.
Zurück zum Zitat Baker, C.H., E.T. Sutton, Z. Zhou, and J.R. Dietz. 1990. Microvascular vasopressin effects during endotoxin shock in the rat. Circulatory Shock 30: 81–95.PubMed Baker, C.H., E.T. Sutton, Z. Zhou, and J.R. Dietz. 1990. Microvascular vasopressin effects during endotoxin shock in the rat. Circulatory Shock 30: 81–95.PubMed
8.
Zurück zum Zitat Albert, M., M.R. Losser, D. Hayon, V. Faivre, and D. Payen. 2004. Systemic and renal macro- and microcirculatory responses to arginine vasopressin in endotoxic rabbits. Critical Care Medicine 32: 1891–8.CrossRefPubMed Albert, M., M.R. Losser, D. Hayon, V. Faivre, and D. Payen. 2004. Systemic and renal macro- and microcirculatory responses to arginine vasopressin in endotoxic rabbits. Critical Care Medicine 32: 1891–8.CrossRefPubMed
9.
Zurück zum Zitat Kopel, T., M.R. Losser, V. Faivre, and D. Payen. 2008. Systemic and hepatosplanchnic macro- and microcirculatory dose response to arginine vasopressin in endotoxic rabbits. Intensive Care Medicine 34: 1313–20.CrossRefPubMed Kopel, T., M.R. Losser, V. Faivre, and D. Payen. 2008. Systemic and hepatosplanchnic macro- and microcirculatory dose response to arginine vasopressin in endotoxic rabbits. Intensive Care Medicine 34: 1313–20.CrossRefPubMed
10.
Zurück zum Zitat Dellinger, R.P., M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, S.M. Opal, et al. 2013. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Medicine 39: 165–228.CrossRefPubMed Dellinger, R.P., M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, S.M. Opal, et al. 2013. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Medicine 39: 165–228.CrossRefPubMed
11.
Zurück zum Zitat Boyd, J.H., C.L. Holmes, Y. Wang, H. Roberts, and K.R. Walley. 2008. Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation 79: 325–31.CrossRefPubMed Boyd, J.H., C.L. Holmes, Y. Wang, H. Roberts, and K.R. Walley. 2008. Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation 79: 325–31.CrossRefPubMed
12.
Zurück zum Zitat Peng, T.C., and C.J. Huang. 2013. Vasopressin inhibits endotoxin-induced upregulation of inflammatory mediators in activated macrophages. Tzu Chi Medical Journal 25: 150–4.CrossRef Peng, T.C., and C.J. Huang. 2013. Vasopressin inhibits endotoxin-induced upregulation of inflammatory mediators in activated macrophages. Tzu Chi Medical Journal 25: 150–4.CrossRef
13.
Zurück zum Zitat Chang, Y.Y., C.H. Yang, S.C. Wang, M.C. Kao, P.S. Tsai, and C.J. Huang. 2015. Vasopressin inhibits endotoxin binding in activated macrophages. The Journal of Surgical Research 197(2): 412–8.CrossRefPubMed Chang, Y.Y., C.H. Yang, S.C. Wang, M.C. Kao, P.S. Tsai, and C.J. Huang. 2015. Vasopressin inhibits endotoxin binding in activated macrophages. The Journal of Surgical Research 197(2): 412–8.CrossRefPubMed
15.
Zurück zum Zitat Guha, M., and N. Mackman. 2002. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. Journal of Biological Chemistry 277: 32124–32.CrossRefPubMed Guha, M., and N. Mackman. 2002. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. Journal of Biological Chemistry 277: 32124–32.CrossRefPubMed
16.
Zurück zum Zitat Tups, A., G.M. Anderson, M. Rizwan, R.A. Augustine, C. Chaussade, P.R. Shepherd, et al. 2010. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signaling in the hypothalamus. Journal of Neuroendocrinology 22: 534–42.CrossRefPubMed Tups, A., G.M. Anderson, M. Rizwan, R.A. Augustine, C. Chaussade, P.R. Shepherd, et al. 2010. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signaling in the hypothalamus. Journal of Neuroendocrinology 22: 534–42.CrossRefPubMed
17.
Zurück zum Zitat Gratacap, M.P., J. Guillermet-Guibert, V. Martin, G. Chicanne, H. Tronchère, F. Gaits-Iacovoni, et al. 2011. Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions. Advances in Enzyme Regulation 51: 106–16.CrossRefPubMed Gratacap, M.P., J. Guillermet-Guibert, V. Martin, G. Chicanne, H. Tronchère, F. Gaits-Iacovoni, et al. 2011. Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions. Advances in Enzyme Regulation 51: 106–16.CrossRefPubMed
18.
Zurück zum Zitat Fung-Leung, W.P. 2011. Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function. Cellular Signalling 23: 603–8.CrossRefPubMed Fung-Leung, W.P. 2011. Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function. Cellular Signalling 23: 603–8.CrossRefPubMed
19.
Zurück zum Zitat Hirsch, E., G. Lembo, G. Montrucchio, C. Rommel, C. Costa, and L. Barberis. 2006. Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing. Thrombosis and Haemostasis 95: 29–35.PubMed Hirsch, E., G. Lembo, G. Montrucchio, C. Rommel, C. Costa, and L. Barberis. 2006. Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing. Thrombosis and Haemostasis 95: 29–35.PubMed
20.
Zurück zum Zitat Lee, P.Y., C.H. Yang, M.C. Kao, N.Y. Su, P.S. Tsai, and C.J. Huang. 2015. Phosphoinositide 3-kinase β, phosphoinositide 3-kinase δ, and phosphoinositide 3-kinase γ mediate the anti-inflammatory effects of magnesium sulfate. The Journal of Surgical Research 197: 390–7.CrossRefPubMed Lee, P.Y., C.H. Yang, M.C. Kao, N.Y. Su, P.S. Tsai, and C.J. Huang. 2015. Phosphoinositide 3-kinase β, phosphoinositide 3-kinase δ, and phosphoinositide 3-kinase γ mediate the anti-inflammatory effects of magnesium sulfate. The Journal of Surgical Research 197: 390–7.CrossRefPubMed
21.
Zurück zum Zitat Tsai, P.S., C.C. Chen, P.S. Tsai, L.C. Yang, W.Y. Huang, and C.J. Huang. 2006. Heme oxygenase 1, nuclear factor E2-related factor 2, and nuclear factor kappaB are involved in hemin inhibition of type 2 cationic amino acid transporter expression and L-arginine transport in stimulated macrophages. Anesthesiology 105: 1201–10.CrossRefPubMed Tsai, P.S., C.C. Chen, P.S. Tsai, L.C. Yang, W.Y. Huang, and C.J. Huang. 2006. Heme oxygenase 1, nuclear factor E2-related factor 2, and nuclear factor kappaB are involved in hemin inhibition of type 2 cationic amino acid transporter expression and L-arginine transport in stimulated macrophages. Anesthesiology 105: 1201–10.CrossRefPubMed
22.
Zurück zum Zitat Chen, C.P., P.S. Tsai, and C.J. Huang. 2012. Anti-inflammation effect of human placental multipotent mesenchymal stromal cells is mediated by prostaglandin E2 via a myeloid differentiation primary response gene 88-dependent pathway. Anesthesiology 117: 568–79.CrossRefPubMed Chen, C.P., P.S. Tsai, and C.J. Huang. 2012. Anti-inflammation effect of human placental multipotent mesenchymal stromal cells is mediated by prostaglandin E2 via a myeloid differentiation primary response gene 88-dependent pathway. Anesthesiology 117: 568–79.CrossRefPubMed
23.
Zurück zum Zitat Gharbi, S.I., M.J. Zvelebil, S.J. Shuttleworth, T. Hancox, N. Saghir, J.F. Timms, et al. 2007. Exploring the specificity of the PI3K family inhibitor LY294002. The Biochemical Journal 404: 15–21.CrossRefPubMedPubMedCentral Gharbi, S.I., M.J. Zvelebil, S.J. Shuttleworth, T. Hancox, N. Saghir, J.F. Timms, et al. 2007. Exploring the specificity of the PI3K family inhibitor LY294002. The Biochemical Journal 404: 15–21.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Collins, C.B., D. Strassheim, C.M. Aherne, A.R. Yeckes, P. Jedlicka, and E.F. de Zoeten. 2014. Targeted inhibition of heat shock protein 90 suppresses tumor necrosis factor-α and ameliorates murine intestinal inflammation. Inflammatory Bowel Diseases 20: 685–94.CrossRefPubMedPubMedCentral Collins, C.B., D. Strassheim, C.M. Aherne, A.R. Yeckes, P. Jedlicka, and E.F. de Zoeten. 2014. Targeted inhibition of heat shock protein 90 suppresses tumor necrosis factor-α and ameliorates murine intestinal inflammation. Inflammatory Bowel Diseases 20: 685–94.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Manerba, M., L. Di Ianni, M. Govoni, M. Roberti, M. Recanatini, and G. Di Stefano. 2016. Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells. European Journal of Pharmaceutical Sciences 96: 37–44.CrossRefPubMed Manerba, M., L. Di Ianni, M. Govoni, M. Roberti, M. Recanatini, and G. Di Stefano. 2016. Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells. European Journal of Pharmaceutical Sciences 96: 37–44.CrossRefPubMed
26.
Zurück zum Zitat Viviani, B., E. Corsini, M. Binaglia, L. Lucchi, C.L. Galli, and M. Marinovich. 2002. The anti-inflammatory activity of estrogen in glial cells is regulated by the PKC-anchoring protein RACK-1. Journal of Neurochemistry 83: 1180–7.CrossRefPubMed Viviani, B., E. Corsini, M. Binaglia, L. Lucchi, C.L. Galli, and M. Marinovich. 2002. The anti-inflammatory activity of estrogen in glial cells is regulated by the PKC-anchoring protein RACK-1. Journal of Neurochemistry 83: 1180–7.CrossRefPubMed
27.
Zurück zum Zitat Holmes, C.L., D.W. Landry, and J.T. Granton. 2003. Science review: Vasopressin and the cardiovascular system part 1—receptor physiology. Critical Care 7: 427–34.CrossRefPubMedPubMedCentral Holmes, C.L., D.W. Landry, and J.T. Granton. 2003. Science review: Vasopressin and the cardiovascular system part 1—receptor physiology. Critical Care 7: 427–34.CrossRefPubMedPubMedCentral
Metadaten
Titel
Phosphoinositide 3-Kinase Is Involved in Mediating the Anti-inflammation Effects of Vasopressin
verfasst von
Woan-Ching Jan
Ming-Chang Kao
Chen-Hsien Yang
Ya-Ying Chang
Chun-Jen Huang
Publikationsdatum
10.12.2016
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 2/2017
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-016-0489-x

Weitere Artikel der Ausgabe 2/2017

Inflammation 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.